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Abstract
Background: From 2007 to 2010, (the southern part of) the Netherlands experienced a large Q fever epidemic,
with more than 4,000 reported symptomatic cases. Approximately 1 – 5% of the acute Q fever patients develop
chronic Q fever. A high IgG antibody titre against phase I of Coxiella burnetii during follow-up is considered a marker
of chronic Q fever. However, there is uncertainty about the significance and cause of persistence of high IgG phase
I antibody titres in patients that do not have any additional manifestations of chronic Q fever. We studied whether
continued or repeated exposure to the source of infection could explain elevated IgG phase I antibody levels.
Methods: A case–control study was performed to analyze predictors for possible chronic Q fever. Possible chronic
Q fever cases (n = 53) are patients with phase I IgG antibody titre ≥1:1,024 at any point in the 9 – 18 months after
acute Q fever diagnosis, with a negative PCR test result for C. burnetii DNA and without other disease manifestations.
Controls (n = 110) are acute Q fever patients that did not develop chronic Q fever, and who consistently had phase I
IgG antibody titre <1:1,024 during the 9 – 18 months follow-up. Binary logistic regression was performed to analyze the
effect of living close to an infected farm on the high antibody titres. A longitudinal analysis described the serological
profiles of cases and controls.
Results: Proximity to infected farms and contact with animal placental material were not associated with an increased
risk for possible chronic Q fever. Possible chronic Q fever patients have high IgG phase II as well as IgG phase I
antibody titres, even after 48 months of follow-up.
Conclusion: We were unable to explain the cause of persistent high IgG phase I titres among possible chronic Q fever
patients by being continuously exposed to the source of infection.
Keywords: Coxiella burnetii, Q fever, The Netherlands, Chronic, Distance
Background
Coxiella burnetii is a gram-negative bacterium that causes
the zoonotic infectious disease Q fever. The primary reser-
voirs for C. burnetii are mainly goats, sheep and cattle
[1-3], which secrete the bacterium in their urine, feces,
milk or birth products. C. burnetii has also been reported
in cats, dogs, birds, horses and rodents [1,2]. Infected
humans may develop acute Q fever, which is a mild, self-
limiting influenza-like illness that is sometimes compli-
cated with pneumonia or hepatitis. Approximately 1 – 5%
of the acute Q fever patients develop chronic Q fever,
which is detected months or years after infection [3-5].
C. burnetii has two antigenic phases: phase I and phase II.
High levels of phase II antibodies are found in acute Q
fever, whereas in chronic Q fever high levels of IgG phase
I antibodies are predominant [6,7]. Acute Q fever patients
with aneurysm, valvular surgery, vascular prosthesis, renal
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insufficiency, pregnancy, and immunosuppression are at
higher risk for developing chronic Q fever [3,4,8].
The primary source of infection is the inhalation of con-
taminated aerosols [1,9,10], that originate directly from an-
imals or from a contaminated environment [9,11]. People
working in certain occupations are considered to be highly
exposed to C. burnetii [1,8,12-19], which includes livestock
farmers, veterinarians, students and personnel of veterinary
schools/universities and veterinary hospitals, slaughter-
house workers, and laboratory workers [1,8,10,15]. Being
present when animals give birth increases the risk of in-
fection, since high concentrations of bacteria are found
in placental material [11,20]. However, occupational ex-
posure alone cannot explain the Q fever epidemic in
the Netherlands. Rather, the highest risk was for people
living close to infected dairy goat farms [21-23]. C. bur-
netii can survive for months in the environment in a
spore-like form, which may be a source of infection for
people that participate in outdoor activities [10]. Envir-
onmental conditions in the surrounding of an infected
farm might play a role in the spread of the infection:
dry soil conditions with little vegetation and high par-
ticulate matter concentrations in the air are possible
risk factors [24-26].
During the years 2007 – 2010, (the southern parts of )
the Netherlands experienced a major Q fever epidemic,
with more than 4,000 reported symptomatic cases. How-
ever, the actual incidence of infection is much higher as
50 – 60% of patients have an asymptomatic C. burnetii
infection [27,28]. Probably due to veterinary hygienic
measures, culling of pregnant goats, and vaccination of
goats, the acute Q fever epidemic in the Netherlands
stopped. Nevertheless, a rising number of chronic Q
fever patients is seen [3,29]. A Dutch Q fever consensus
group has set up criteria for the diagnosis of proven,
probable, and possible chronic Q fever (Table 1) [3,4].
The Dutch chronic Q fever database listed 284 patients
with chronic Q fever: 151 patients with proven chronic
Q fever, 64 with probable, and 69 with possible chronic
Q fever [30]. Distinction between the categories of
chronic Q fever is important in order to understand
whether treatment needs to be initiated. Frequent moni-
toring is warranted, which consists of a three monthly
clinical and microbiological follow-up. Radiographical
imaging (echocardiogram, PET/CT) should be per-
formed when clinical status stagnates or worsens. Pos-
sible chronic Q fever patients solely have a phase I IgG
antibody titre of ≥1:1,024, without any of the mentioned
manifestations in the category probable and proven
chronic Q fever. In general, no antibiotic treatment is
initiated in these patients when PCR is negative and no
risk factors are identified [3,4].
There is uncertainty about the cause of persistence of
high antibody titres against C. burnetii in possible chronic
Q fever patients that do not have any additional manifes-
tations. Host factors are likely to be of importance but
one of the hypotheses is that continuous exposure to an
infection source or boosting causes persistence of high
antibody titres. The aims of the current study are (1) to
assess whether proximity to the source of infection
could predict the persistent high phase I IgG antibody
titres among possible chronic Q fever patients; (2) to
study the effect of living close to an infected farm on
the high levels of phase I and II IgG antibody titres; and
(3) to study the serological follow-up profiles of patients




A case–control study was performed to evaluate whether
continued exposure to the source of infection is associated
with persistent high phase I IgG antibody titres among
possible chronic Q fever patients, and specifically, to study
the effect of living close to an infected farm on the high
levels of IgG phase I and phase II antibody titres. In
addition, a longitudinal cohort study was performed to
describe phase I and II IgG antibody titres among patients
without chronic Q fever and possible chronic Q fever
patients, four years after acute Q fever diagnosis.
Table 1 Criteria for diagnosis of chronic Q fever,
according to the Dutch Q fever consensus group [3]
Classification Definition
Proven • Positive C. burnetii in tissue or blood in absence of
acute Q fever infection OR
• IFA phase I IgG titer ≥1:1,024 with definite endocarditis
according to the revised Duke criteria* OR
• IFA phase I IgG titer ≥1:1,024 with vascular infection
diagnosed with PET/CT, CT, MRI or ultrasound testing
Probable IFA phase I IgG titer ≥1:1,024 with one of the following
manifestations:
• Valvular deviation that does not meet the definition of
endocarditis according to the Duke criteria
• Aneurysm, valvular- or vascular prosthesis without an
infection on PET/CT, CT, MRI or ultrasound testing
• Suspicion of osteomyelitis or hepatitis as an expression
of chronic Q fever
• Pregnancy




Possible Solely a phase I IgG ≥1:1,024¥, without any of the
manifestations mentioned in the categories proven
and probable.
*A set of clinical criteria for the diagnosis of infective endocarditis.
¥Phase I IgG antibody titer ≥1:1,024 is within the JBZ measured between
9 – 18 months after acute Q fever diagnosis.




The study population consisted of Q fever patients, that
were recruited from the Jeroen Bosch Hospital (JBH) in
’s-Hertogenbosch, Bernhoven Hospital (BH) in Uden,
and from the Laboratory for Pathology and Medical
Microbiology (PAMM) in Veldhoven. Approval was ob-
tained from the Medical Ethical Committee (METC
Brabant) to approach the study population in the con-
text of the serological follow-up study within the JBH
(Q-HORT) (reference number: NL35654.028.11). The
Q-HORT study included patients ≥18 years, that were di-
agnosed with acute Q fever in the years 2007 – 2009, with
a follow-up sample submitted approximately 12 months
after diagnosis. These patients were invited for this follow-
up study approximately four years after the acute Q fever
diagnosis. Written informed consent was obtained at the
time of the Q-HORT study, which also included permis-
sion for being contacted for future research. Actual per-
mission of participation in the current study was obtained
via oral informed consent before the telephonic interview
took place.
Cases
Cases (n = 53) are possible chronic Q fever patients,
defined as having a serological profile with phase I
IgG ≥1:1,024 at any point between the 9 – 18 months
after acute Q fever diagnosis; having a PCR-negative test
result; and not fulfilling the criteria for probable or
proven chronic Q fever (Table 1). Several possible
chronic Q fever patients, of whom the date of acute Q
fever diagnosis was unknown, were identified as possible
chronic Q fever case due to the persistence of high
phase I IgG antibody titres. For these patients, the date
of acute Q fever was assumed to be one year before the
development of the positive serologic profile of phase I
IgG ≥1:1,024. Cases were included when diagnosed with
possible chronic Q fever in the period from June 2008
until December 2012 and when being ≥18 years of age
at the time of acute Q fever diagnosis.
According to the Q fever guideline of the JBH, acute
Q fever patients with a high risk for chronic Q fever de-
velopment were serologically and clinically followed on
the 3th, 6th, 9th and 12th month after acute Q fever diag-
nosis in order to monitor the development of chronic Q
fever. In case of persistence of high levels of phase I and
II IgG antibody titers and in the context of the Q-HORT
study, several patients from the JBH, BH and PAMM
were followed for a longer period of time, which is 24,
36 and 48 months after acute Q fever diagnosis.
Controls
Controls (n = 110) are acute Q fever patients who did not
develop chronic Q fever and who had phase I IgG <1:1,024
test results between the 9 – 18 months after acute Q
fever diagnosis. Controls were randomly selected from
participants of the Q-HORT study, until a 1:2 case–
control ratio was reached.
Data collection
Clinical data was collected from the hospital information
systems. Phase I and II IgG data was collected from the
laboratory database of the Regional Laboratory of Med-
ical Microbiology and Infection Control of the JBH, that
performs Q fever diagnostic tests for the JBH and the
BH. The PAMM provided serological data of their pos-
sible chronic Q fever patients that were included in this
study. Immunofluorescence Assay (IFA; Focus Diagnostics,
Cypress, CA, USA) was used to detect IgG antibodies
against C. burnetii phase I and II antigens.
A telephonic interview was performed to collect infor-
mation about medical risk factors for chronic Q fever
and to identify possible exposure to the source of infec-
tion. Source of infection was defined as having occupa-
tional exposure (veterinarian, farmer, laboratory worker,
slaughterhouse worker, animal transporter) and/or phys-
ical and frequent (minimum one time per week) contact
with animals (goats, cattle, sheep, cats, dogs, birds, horses,
rodents) and/or animal products (fertilizer, hay/straw, pla-
cental material, fur/skin/wool) and/or living relatively
close to an infected farm from 2007 – 2013.
For the analysis on the effect of proximity of residen-
tial addresses to an infected farm on the phase I and II
IgG antibody titres, farms were selected that were bulk
tank milk positive or that had Q fever-induced abortion
problems. The distance of each patient to each infected
farm was calculated based on the exact coordinates of the
infected farms (provided by the Ministry of Economic
Affairs, Agriculture and Innovation) and the coordinates
of the six-digit zip codes, i.e. street-level, of the patients
(provided by the Municipal Health Services).
Statistical data analysis
Retrospective case–control study
A Chi-square test was used for the univariate analyses for
comparison of proportions between cases and controls.
Within the case–control study two separate analyses
were performed. The first analysis was a multivariable
logistic regression with backward selection method to
investigate which variables are predictors of possible
chronic Q fever. All variables with a p-value <0.20 in the
univariate analysis were included in multivariable logistic
regression analysis. The second analysis consisted of a
binary logistic regression analysis in which the effect of
proximity of residential address to an infected farm on
the phase I and II IgG titres 9 – 18 months after acute
Q fever diagnosis was studied. This second analysis was
performed for the case–control study population and for
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all patients eligible to be invited in the Q-HORT study,
consisting of acute Q fever, possible, probable and proven
chronic Q fever patients. For both groups the outcome
phase I or II IgG antibody titres was dichotomized
in <1:1,024 and ≥1:1,024. The living distance to an infected
farm was categorized in 0 – 2,000 meter (m), >2,000 –
5,000 m and >5,000 m, according to Schimmer et al. [23].
To evaluate the goodness of fit of the prediction
model, the −2 Log likelihood and Nagelkerke R Square
were calculated. The area under the Receiver Operating
Characteristic (ROC) curve and 95% confidence interval
(95% CI) were calculated in order to identify how well
the prediction model distinguishes acute Q fever pa-
tients from possible chronic Q fever patients.
Longitudinal cohort study
Serological follow-up data for possible chronic Q fever
patients were reported for 24, 36, and 48 months after
acute Q fever diagnosis. The Chi-square test was used to
identify whether there was a difference at 48 months
after acute Q fever diagnosis in phase I and II IgG anti-
body titres between patients without chronic Q fever and
possible chronic Q fever patients. Serological follow-up
data were used from existing data from the same study
population as the case–control study.
Analyses for both the case–control and longitudinal
study were performed using the statistical software IBM




From the 77 eligible possible chronic Q fever patients,
24 patients were excluded because of: progression to
probable chronic Q fever during follow-up (n = 8), death
(n = 7), loss to follow-up (n = 3), not available for tele-
phonic interview because of bad health status (n = 2), no
phase I IgG titres available between 9 – 18 months after
acute Q fever diagnosis but possible chronic Q fever di-
agnosed later (n = 2), not willing to participate in add-
itional research (n = 1) and being recently identified as a
possible chronic Q fever patient but not being checked
in the clinic for possible risk factors (n = 1) (Figure 1).
From the 1,937 acute Q fever patients that were eligible
to participate in the Q-HORT study, 62 patients were
excluded due to development of chronic Q fever, and 38
due to not willing to participate in additional research
(Figure 1).
Baseline characteristics
In total, 62.3% (n = 33) of the possible chronic Q fever
patients and 68.2% (n = 75) of the patients without
chronic Q fever were exposed to minimum one of the
variables of the source of infection. Except for contact
with placental material, which was reported by very few
participants, there were no significant differences be-
tween cases and controls in baseline characteristics and
risk factors (Table 2).
Figure 1 Inclusion/exclusion criteria for patients without chronic Q fever and possible chronic Q fever patients. Legend: *JBH: Jeroen
Bosch Hospital; BH: Bernhoven Hospital; PAMM: Laboratory for Pathology and Medical Microbiology.
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Table 2 Baseline characteristics of study population
Possible chronic Q fever n = 53 Non chronic Q fever n = 110 p-value
Gender (male) 30 (56.6%) 53 (48.2%) 0.314
Mean age ± SD 56.3 (±10.7) 53.3 (±12.1) 0.128
Living area (rural) 36 (67.9%) 65 (59.1%) 0.227
Participant of Q-HORT study 21 (39.6%) 110 (100%) -
Year of acute Q fever diagnosis 0.454
2007 4 (7.5%) 24 (21.8%)
2008 16 (30.2%) 41 (37.3%)
2009 22 (41.5%) 45 (40.9%)
2010/2012 2 (3.8%) 0 (0.0%)
Unknown 9 (17.0%) 0 (0.0%)
Hospitalization due to Q fever 10 (18.9%) 18 (16.4%) 0.691
Smoker 11 (21.2%) 38 (34.9%) 0.077
Co-morbidity
Cardiovascular disease 0 (0%) 7 (6.4%) 0.060
Immunosuppressed 3 (5.7%) 5 (4.5%) 0.758
Non-hematologic cancer 4 (7.5%) 3 (2.7%) 0.155
Pregnancy 1 (1.9%) 4 (3.6%) 0.544
Renal failure 1 (2.0%) 0 (0.0%) 0.141
Diabetes 5 (9.4%) 6 (5.5%) 0.343
Occupational risk 2 (3.8%) 3 (2.7%) 0.717
Contact animal products
Fertilizer 8 (15.1%) 9 (8.2%) 0.176
Hay and straw 7 (13.2%) 14 (12.7%) 0.932
Placental material 4 (7.5%) 1 (0.9%) 0.021
Fur/skin/wool 30 (56.6%) 63 (57.3%) 0.936
Intensity contact fertilizer 0.602
≤3 times per week 2 (3.8%) 2 (1.8%)
>3 times per week 5 (9.6%) 6 (5.5%)
Intensity contact hay and straw 0.640
≤3 times per week 2 (3.8%) 7 (6.4%)
>3 times per week 5 (9.4%) 7 (6.4%)
Intensity contact placental material 0.036
≤3 times per week 1 (1.9%) 1 (0.9%)
>3 times per week 3 (5.7%) 0 (0.0%)
Intensity contact fur/skin/wool 0.446
≤3 times per week 1 (1.9%) 7 (6.4%)
>3 times per week 29 (54.7%) 55 (50.0%)
Contact animals
Goats, cows or sheep 5 (9.4%) 6 (5.5%) 0.343
Cats 13 (24.5%) 19 (17.3%) 0.275
Dogs 19 (35.8%) 46 (41.8%) 0.466
Birds (including chicken and ducks) 2 (3.8%) 13 (11.8%) 0.096
Horses 5 (9.4%) 9 (8.2%) 0.789
Rodents 3 (5.7%) 7 (6.4%) 0.861
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Multivariable logistic regression analysis
The variables age, smoking, contact with fertilizer, con-
tact with placental material, contact with birds, and liv-
ing distance to an infected farm had a p-value <0.20 in
the univariate analysis and were included in multivariable
regression analysis. The variable gender had a p-value
of >0.20 in the univariate analysis, but was included
nevertheless due to biological plausibility [18,21,31].
The variables cardio-vascular disease, non-hematologic
cancer, renal failure, and intensity of the contact with
placental material had a p-value <0.20 in univariate
analysis, but were not included in multivariable regres-
sion analysis due to the small numbers (Table 2). The
final prediction model did not show any significant associ-
ation between exposure variables and possible chronic Q
fever (Table 3). The best fitting model included the vari-
ables smoking, contact with placental material and contact
with birds (−2 Log likelihood is 191.7 and Nagelkerke
R2 = 0.092). The area under the ROC curve (AUC) shows
that the final model poorly discriminates between possible
chronic Q fever patients and acute Q fever patients that
did not develop chronic Q fever (AUC 0.70, 95% CI 0.61 –
0.78, p = 0.001).
Within this case–control study, no significant effect
was observed for proximity of residential addresses to an
infected farm and the phase I and II IgG antibody titres
at the 9 – 18 months after acute Q fever diagnosis.
Within the entire Q-HORT study population (n = 1,937),
phase I IgG antibody titres at the 9 – 18 months after acute
Q fever diagnosis were lower for those living >2,000 –
5,000 m from an infected farm compared to the refer-
ence group living further away (p = 0.029). This differ-
ence was not observed for IgG II antibodies (Table 4).
Serological follow-up
On the 24th and 36th month after acute Q fever diagno-
sis, the highest frequencies of possible chronic Q fever
patients were observed in the category phase I IgG anti-
body titres 1:1,024 – 1:2,048, and on the 48th month
after acute Q fever diagnosis, in the category phase I
IgG antibody titres 1:256 – 1:512.
We observed statistically significantly (p = 0.001) more
possible chronic Q fever patients than patients without
chronic Q fever in the higher categories of phase I and
II IgG antibody titres on the 48th month after acute Q
fever diagnosis. Among the patients without chronic Q
fever, phase I IgG antibody titres remained low (highest
frequencies observed in the category 1:32 – 1:128), and
phase II IgG antibody titres remained high (highest fre-
quencies observed in the category 1:256 – 1:512) during
follow-up (Table 5).
Discussion
The present study provides no evidence that Q fever pa-
tients with persistent high phase I IgG antibody levels,
classified as possible chronic Q fever, had higher expos-
ure to infection sources than Q fever patients with low
phase I IgG titres and thus without chronic Q fever.
Continuous boosting of the immune system might not
be a major factor in development of possible chronic Q
fever, i.e. high phase I IgG antibody titres. This suggests
that host-related factors like endocarditis and aneurysm
are more important.
Table 2 Baseline characteristics of study population (Continued)
Others (rabbit, fish, pig, tortoise) 2 (3.8%) 10 (9.1%) 0.659
Intensity contact animals 0.877
≤3 times per week 2 (3.8%) 6 (5.5%)
>3 times per week 28 (52.8%) 59 (53.6%)
Distance from house to infected farm 0.198
0 – 2,000 m 7 (13.2%) 24 (22.0%)
>2,000 – 5,000 m 21 (39.6%) 48 (44.0%)
>5,000 m 25 (47.2%) 37 (33.9%)
Table 3 Univariate and multivariable analysis
Univariate analysis
OR (95% CI) p-value
Age 1.56 (0.81 – 3.01) 0.186
Gender 0.71 (0.37 – 1.38) 0.314
Smoking 0.50 (0.23 – 1.09) 0.080
Contact fertilizer 2.00 (0.72 – 5.51) 0.182
Contact placental material 8.90 (0.97 – 81.69) 0.053
Contact with birds 0.29 (0.06 – 1.35) 0.115
Living distance to infected farm
<2,000 – 5,000 m 1.50 (0.56 – 4.02) 0.420
>5,000 m 2.32 (0.87 – 6.20) 0.094
Multivariable analysis
OR (95% CI) p-value
Smoking 0.51 (0.23 – 1.13) 0.096
Contact placental material 7.91 (0.85 – 73.99) 0.070
Contact with birds 0.30 (0.07 – 1.41) 0.127
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Several studies described that occupational exposure
or high exposure to the source of infection increases
the risk for acquiring Q fever [1,8,12-19]. However,
there are also studies that showed that living close to
an infected dairy goat farm increases the risk for ac-
quiring acute Q fever [22,23,26] without occupational
exposure playing a role [22]. People without direct con-
tact with animals or animal products can also become
infected, for example laundry workers that handle con-
taminated clothing [8,10]. A study on the risk of ac-
quiring Q fever on a livestock farm concluded that
contact with the farm environment rather than contact
with a specific farm animal is related to the risk of Q
fever [32].
In our case–control study, we did not find an effect of
exposure to the source of infection on persistent high
phase I IgG antibody titres among possible chronic Q
fever patients. We defined exposure to the source of in-
fection as having occupational exposure and/or having
at least one time per week physical contact with animals
and/or animal products. However, maybe intense con-
tact with one certain animal or animal product might be
enough to acquire persistence of high levels of phase I
IgG antibody titres.
We also did not find an effect of living relatively close
to an infected farm and acquiring possible chronic Q
fever. Contradictory, we found a lower risk for those liv-
ing >2,000 – 5,000 m from an infected farm compared
Table 4 Effect of living distance on the phase I and II IgG antibody titres
Living distance from infected farm in meters,
within case–control study†
phase I IgG <1:1,024 / ≥1:1,024 phase II IgG <1:1,024 / ≥1:1,024
OR (95% CI) p-value OR (95% CI) p-value
>5,000 ref* ref* ref* ref*
>2,000 – 5,000 0.42 (0.16 – 1.11) 0.079 0.59 (0.23 – 1.51) 0.274
0 – 2,000 0.67 (0.33 – 1.36) 0.264 1.00 (0.46– 2.18) 0.992
Living distance from infected farm in meters,
within Q-HORT study¥
phase I IgG <1:1,024 / ≥1:1,024 phase II IgG <1:1,024 / ≥1:1,024
OR (95% CI) p-value OR (95% CI) p-value
>5,000 ref* ref* ref* ref*
>2,000 – 5,000 0.52 (0.28 – 0.93) 0.029 0.98 (0.76 – 1.25) 0.843
0 – 2,000 0.65 (0.41 – 1.03) 0.066 0.98 (0.79 – 1.22) 0.857
*ref = reference category.
†Case–control study exists of acute and possible chronic Q fever patients from the Jeroen Bosch Hospital, Bernhoven Hospital and Laboratory for Pathology and
Medical Microbiology.
¥Q-HORT study exists of acute Q fever, possible, probable and proven chronic Q patients from the Jeroen Bosch Hospital, Bernhoven Hospital and Laboratory for
Pathology and Medical Microbiology.
Table 5 Serological follow-up of cases and controls
Possible chronic Q fever Possible chronic Q fever
Antibody titers on the 24th month
after acute Q fever diagnosis
IgG phase I IgG phase II Antibody titers on the 36th month
after acute Q fever diagnosis
IgG phase I IgG phase II
<1:32 0 (0.0%) 0 (0.0%) <1:32 0 (0.0%) 0 (0.0%)
1:32 – 1:128 2 (7.4%) 0 (0.0%) 1:32 – 1:128 1 (4.8%) 0 (0.0%)
1:256 – 1:512 7 (25.9%) 2 (7.4%) 1:256 – 1:512 7 (33.3%) 3 (14.3%)
1:1,024 – 1:2,048 12 (44.4%) 13 (48.1%) 1:1,024 – 1:2,048 10 (47.6%) 12 (57.1%)
≥1:4,096 6 (22.2%) 12 (44.4%) ≥1:4,096 3 (14.3%) 6 (28.6%)
IgG phase I IgG phase II
Antibody titers on the 48th month





Antibody titers on the 48th month





<1:32 1 (2.9%) 55 (51.0%) <1:32 0 (0.0%) 3 (2.8%)
1:32 – 1:128 6 (17.6%) 47 (43.9%) 1:32 – 1:128 0 (0.0%) 31 (29.0%)
1:256 – 1:512 11 (32.4%) 5 (4.7%) 1:256 – 1:512 5 (14.7%) 51 (47.7%)
1:1,024 – 1:2,048 10 (29.4%) 0 (0.0%) 1:1,024 – 1:2,048 19 (55.9%) 19 (17.8%)
≥1:4,096 6 (17.6%) 0 (0.0%) ≥1:4,096 10 (29.4%) 3 (2.8%)
p-value =0.001* p-value =0.001*
*Chi-square test is used to calculate the p-value.
†There were three patients without chronic Q fever of which serological data of four years after acute Q fever diagnosis was missing.
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to those living further away. Possibly, distance from resi-
dential address to an infected farm is only important for
becoming acutely infected and not for the development
of high phase I and II IgG antibody titres and therefore
the development of possible chronic Q fever.
This study showed that during follow-up, several possible
chronic Q fever patients showed persistent high phase I
IgG antibody titres up to several years after acute Q fever
diagnosis. This should be taken into account when diag-
nosing a patient with long-term persistence of antibodies
as possible chronic Q fever, as described before [33].
The study has several limitations. First, due to the
small sample size, only a small number of patients were
found to have close and frequent contact with animals
and animal products. Therefore, findings (although not
significant) of this study should be interpreted with cau-
tion. For example, contact with placental material seems
to be an important predictor due to the biological
plausibility and the high OR of 7.91 found in this study.
However, an extremely wide 95% CI was found, reflect-
ing the small number of patients exposed to placental
material. It is clear that small sample size is a major
limitation of our study. With the available number of
cases and controls, and exposure defined as living at
5,000 m or less from an infected farm, the power of the
study was only 36%. The study population size was suffi-
ciently powered (80%) to detect an odds ratio of 3 with a
significance level of 5%.
This study was performed within an average popula-
tion that does not have occupational exposure and/or
frequent contact with animals and/or animal products.
In a population with high occupational exposure (like
farmers and veterinarians), having close and frequent
contact with animals and animal products is more likely.
It cannot be ruled out that high exposure to the source
of infection plays a role in persistent high antibody titres
in the occupationally exposed, as has also been shown in
a study among wool workers in Belgium [34]. An ongoing
study among veterinarians with three-year follow-up
could possibly clarify this issue. Furthermore, due to the
small sample size we were not able to include all possible
predictors in the backward selection method. Therefore,
we may have missed some relevant predictors for possible
chronic Q fever. Based on the research question of this
study, the priority of inclusion of variables in multivariable
logistic regression analysis was given to variables that in-
cluded contact with animals and animal products.
Secondly, in our analysis we assumed that a patient
might have been become infected by the closest farm to
the home address, which not necessarily would have
been the case. Also, it is uncertain whether the study
population was exposed to the source of infection before
the occurrence of their Q fever infection. Therefore, the
exact causal relation between patient and farm infection
could not be identified, which may explain the non-
significant effect we found between living distance to an
infected farm and the high levels of phase I and II IgG
antibody titres.
Finally, the use of a retrospective telephonic question-
naire as a method of data collection might have caused
bias. The questionnaire included questions about expos-
ure to the source of infection from 2007, which may
have caused recall bias. However, we expect recall bias
to be limited since questions were about being exposed
on a regular basis, which is expected to be well
reminded by the patient. Also, a telephonic question-
naire may have led to information bias by navigating the
answer of the patient to a certain direction in case of
doubt. However, compared to a paper questionnaire, a
telephonic questionnaire has the benefit of giving a bet-
ter insight in the degree of exposure over the past years
and clarification could be given when a question was
misunderstood, which limits information bias. Further-
more, knowing the disease status of the patient at data
collection, might have led to information bias. However,
by using the same structural questionnaire among the
study population, this was less likely to occur.
Conclusions
Serological follow-up until four years after acute Q fever
diagnosis, showed that phase I IgG antibody titres slightly
decreased and phase II antibody titres remained high
among possible chronic Q fever patients. It is still unclear
which factors cause the persistence of high phase I anti-
body titres among possible chronic Q fever patients. No
clear relation could be established between exposure to
the source of infection, proximity of residential addresses
to an infected farm, and the development of possible
chronic Q fever. It is unknown whether possible chronic
Q fever patients have actual persistence and replication of
C. burnetii or whether there still is evidence of boosting.
Further research is needed to assess other potential pre-
dictors, which could focus on patients genetic tendency to
develop high levels of antibodies for a prolonged period of
time in response to an infection.
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